Ceftriaxone in the Management of Bipolar Depression

• Status: Terminated
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: Stanley Medical Research Institute
• Treatments: Ceftriaxone

Criteria

Inclusion Criteria:

• DSM-IV diagnosis of bipolar disorder

• Presence of a current major depressive episode on the SCID

• Score of 17 or greater on the HDRS

• Failure to respond to two previous medication trials

• Capable of giving voluntary written consent

Exclusion Criteria:

• Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis

• Significant current substance dependence/abuse within 3 months preceding the trial

• Significant history of intravenous drug abuse

• Active suicidal ideation

• Pregnant/lactating mothers

• Significant medical history

• Patients on anticoagulation treatment

• Patients who test positive for HIV or Hep B or C